Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Including medical news, pharmaceutical industry news, new drug approvals, applications and clinical trial results.
Daily MedNews
Here are some of the latest health and medical news developments, compiled by editors of HealthDay:
Clinical Trial Ended for Prostate Cancer Vaccine
Biotech startup Cell Genesys has ended a clinical study of its prostate cancer vaccine GVAX due to a...
-- Here are the latest clinical trials, courtesy of CenterWatch:
Eczema (Atopic Dermatitis)
If you are aged 18 to 65, have eczema, and are in good general health, you may be eligible for this study.
The research site is in Raleigh, N.C.
More...
THURSDAY, Aug. 28 -- The metal cadmium plays a major role in causing emphysema, and even low-level exposure through secondhand smoke and other sources can increase the risk of lung disease, a new study says.
The University of Michigan School of...
THURSDAY, Aug. 28 (HealthDay) -- One in four women in the United States carries a bacterium that could cause a debilitating and life-threatening infection in their newborn babies. And many don't know it.
Infants who contract Group B streptococcus...
-- A herniated (sometimes called "ruptured") disk in the back or neck can cause severe pain and numbness.
Disks are the soft, rubbery pads found between the spine's vertebrae. When stressed or overused from wear-and-tear, the center of the disk can...
Pharma Industry News
LONDON, & ALISO VIEJO, California, Aug. 28, 2008-GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International (NYSE: VRX) today announced that they have entered into an exclusive worldwide collaboration agreement for the investigational drug...
LOUISVILLE, Colo., August 27, 2008 /PRNewswire-FirstCall/ -- Replidyne, Inc. today announced the restructuring of its operations reducing its current employee headcount by approximately 80% to 5 employees in actions that are scheduled to take place...
From Marketwire (August 28, 2008)
BRUSSELS, BELGIUM, August 28 / MARKET WIRE/ --UCB has launched "SHAPE", a major global project to realize its transformation into a focused specialist company in CNS (Central Nervous System) and immunology disease...
NICE Final Guidance Recommends Lucentis As Cost-Effective Treatment for Wet AMD, a Leading Cause of Blindness
Lucentis is only approved therapy to demonstrate improvement in vision and vision-related function in vast majority of wet AMD...
- Clinical data showing unprecedented 89% reduction in risk of GIST relapse with use of Gleevec after surgery are basis for FDA, EMEA, Swissmedic filings
EAST HANOVER, N.J., August 27, 2008 /PRNewswire/ -- Novartis announced today that Gleevec(R)...
New Drug Approvals
WOODCLIFF LAKE, N.J., August 23, 2008 /PRNewswire/ -- Eisai Corporation of North America and its partner Helsinn Healthcare SA today announced that the U.S. Food and Drug Administration (FDA) has approved a new oral formulation of Aloxi...
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug 22, 2008 - Amgen Inc. (NASDAQ: AMGN) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nplate (romiplostim), the first and only platelet producer for the...
SUMMIT, N.J.--(BUSINESS WIRE)--Aug 21, 2008 - Celgene Corporation today announced Vidaza (azacitidine) received expanded U.S. Food and Drug Administration (FDA) approval to reflect new overall survival achieved in the AZA-001 survival study of...
WASHINGTON, August 15, 2008 /PRNewswire/ -- Prestwick Pharmaceuticals, Inc., a privately-held pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Xenazine (tetrabenazine) for the treatment of chorea...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug 11, 2008 - Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Viread (tenofovir disoproxil fumarate) for the treatment of chronic...
New Drug Applications
TITUSVILLE, N.J., August 26, 2008 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that the Food and Drug Administration (FDA) has asked for additional data before it will approve the company's...
VANCOUVER and DEERFIELD, IL, August 11, 2008 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") today announced that they have received an action letter dated August 8, 2008 from the...
BRIDGEWATER, N.J., August 08, 2008 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that U.S. Food and Drug Administration (FDA) has assigned priority review status for its New Drug Application (NDA) for Multaq (dronedarone). The priority...
HORSHAM, Pa., August 08, 2008 /PRNewswire/ -- Centocor, Inc., today announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline for the Biologic License Application for ustekinumab, a subcutaneous biologic therapy, by...
EXTON, Pa.--(BUSINESS WIRE)--Jul 30, 2008 - Othera Pharmaceuticals, Inc., announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for OT-730, an oculoselective beta-blocker, as a...
Clinical Trials
BETHESDA, Md., Aug. 27, 2008--A brain chemical that plays a role in long term memory also appears to be involved in regulating how much people eat and their likelihood of becoming obese, according to a National Institutes of Health study of a rare...
Further validation of Heptares' StaRT technology
LONDON, Aug. 28, 2008--Heptares Therapeutics Ltd, the drug discovery company focused on the design and development of novel drugs based on G-protein-coupled receptors (GPCRs), notes that a new...
Results Presented at the Australian and New Zealand Bone and Mineral Society (ANZBMS) Annual Meeting
HOPKINTON, Mass., Aug. 28 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc., , announced that data from preclinical studies of the Company's...
WARREN, N.J.--(BUSINESS WIRE)--Aug 28, 2008 - In patients with diabetes, the CYPHER(R) Sirolimus-eluting Coronary Stent outperformed the Taxus(R) Stent with significantly lower rates of in-segment restenosis (a reblockage within the stented area),...
COLUMBIA, Md.--(BUSINESS WIRE)--Aug. 28, 2008 - CELSION CORPORATION (NASDAQ: CLSN) announced today that the interim results from its second Phase I liver cancer confirmation study of ThermoDox(R) used in combination with Radio Frequency Ablation...
More News Resources
Daily MedNews
Pharma Industry News
New Drug Applications
New Drug Approvals
Clinical Trial Results
Generic Drug Approvals
